{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:46:09Z","timestamp":1790027169375,"version":"4.0.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunocompromised persons are at high risk of persistent Human Papilloma Virus (HPV) infection and associated diseases. Few studies evaluated HPV vaccines in immunocompromised persons. This study aimed to evaluate the quadrivalent HPV vaccine (4vHPV) immunogenicity and safety in solid organ transplant (SOT) recipients, in comparison to immunocompetent women (IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Open-label clinical trial that enrolled SOT recipients and immunocompetent women aged 18 to 45 years. All participants received three doses of 4vHPV vaccine. Blood samples were drawn for evaluation of immune responses at baseline and one month after the third vaccination. Seroconversion rates and antibody geometric mean concentration (GMC) against HPV 6, 11, 16, 18, 31, 35, 52 and 58 were measured with in-house multiplexed serology assay (xMAP technology). Follow-up for the local and systemic adverse events (AEs) continued for seven days after each vaccination. Severe AEs were evaluated throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      125 SOT and 132 immunocompetent women were enrolled; 105 (84%) SOT and 119 (90%) immunocompetent women completed the study. At baseline, HPV seropositivity was not significantly different between groups. Seroconversion rates were significantly lower in SOT (HPV18, 57%; HPV6 and 16, 69%; and HPV11, 72%) than in immunocompetent women (100% seroconversion to all vaccine types) (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001). Antibody GMCs of all four HPV vaccine types were also significantly lower in SOT (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001). Pain in the injection site and headache were the most frequent adverse event in both groups. Local pain was more frequent in immunocompetent women than in SOT recipients. Rates of other AEs were comparable in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>4vHPV vaccine was well-tolerated by SOT recipients. We found strong evidence of lower humoral immune responses to 4vHPV vaccine in SOT compared to immunocompetent women, which strengthen recommendation of routine cervical cancer screening in SOT recipients regardless of HPV vaccination status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2024.1452916","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:52:13Z","timestamp":1730703133000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant"],"prefix":"10.3389","volume":"14","author":[{"given":"Karina Takesaki","family":"Miyaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Melo","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Levi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Soares","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Nazareth","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyca Suzuki","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maricy","family":"Tacla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Paula","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mayaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Marli Christovam","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/infdis\/jiy107","article-title":"Seroprevalences of antibodies to 11 human papillomavirus (HPV) types mark cumulative HPV exposure","volume":"218","author":"Artemchuk","year":"2018","journal-title":"J. Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1093\/cid\/ciaa1897","article-title":"Immunogenicity and safety of the 9-Valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)","volume":"73","author":"Boey","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/03008916231208344","article-title":"HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination","volume":"110","author":"Bogani","year":"2024","journal-title":"Tumori"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1375","article-title":"The remarkable impact of bivalent HPV vaccine in Scotland","volume":"365","author":"Brotherton","year":"2019","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.36129\/jog.2023.144","article-title":"State of the art on HPV-related cervical lesions","volume":"36","author":"D\u2019Aug\u00e8","year":"2024","journal-title":"Ital. J. Gyn\u00e6cology Obstetrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jcv.2012.12.004","article-title":"Serum antibodies to human papillomavirus (HPV) pseudovirions correlate with natural infection for 13 genital HPV types","volume":"56","author":"Faust","year":"2013","journal-title":"J. Clin. Virol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1099\/vir.0.019349-0","article-title":"Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads","volume":"91","author":"Faust","year":"2010","journal-title":"J. Gen. Virol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1016\/j.vaccine.2011.07.007","article-title":"The first international standard for antibodies to HPV 16","volume":"29","author":"Ferguson","year":"2011","journal-title":"Vaccine"},{"key":"B10","volume-title":"Guidance for Industry - Toxicity grading scale for Healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","year":"2007"},{"key":"B11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/petr.12226","article-title":"Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients","volume":"18","author":"Gomez-Lobo","year":"2014","journal-title":"Pediatr. Transplant."},{"key":"B12","doi-asserted-by":"publisher","first-page":"867.e1","DOI":"10.1016\/j.jaad.2010.12.050","article-title":"Human papillomavirus-related genital disease in the immunocompromised host: Part I","volume":"66","author":"Gormley","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-1759(02)00334-4","article-title":"Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels","volume":"271","author":"Grabowska","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1097\/MIB.0b013e318281341b","article-title":"Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease","volume":"19","author":"Jacobson","year":"2013","journal-title":"Inflammation Bowel Dis."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070135","article-title":"Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis","volume":"378","author":"Kechagias","year":"2022","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1111\/ajt.12329","article-title":"Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients","volume":"13","author":"Kumar","year":"2013","journal-title":"Am. J. Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1111\/ajt.12472","article-title":"HPV-related cancers after solid organ transplantation in the United States","volume":"13","author":"Madeleine","year":"2013","journal-title":"Am. J. Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"B19","volume-title":"INFORME T\u00c9CNICO SOBRE A VACINA PAPILOMAV\u00cdRUS HUMANO (HPV) NA ATEN\u00c7\u00c3O B\u00c1SICA","year":"2013"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262724","article-title":"Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil","volume":"17","author":"Miyaji","year":"2022","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study","volume":"72","author":"Mok","year":"2013","journal-title":"Ann. Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00046","article-title":"Human papillomavirus vaccination in male and female adolescents before and after kidney transplantation: A pediatric nephrology research consortium study","volume":"8","author":"Nailescu","year":"2020","journal-title":"Front. Pediatr."},{"key":"B23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2215\/CJN.09690915","article-title":"Immunogenicity of human papillomavirus recombinant vaccine in children with CKD","volume":"11","author":"Nelson","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill"},{"key":"B25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0022-1759(95)00067-k","article-title":"Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model","volume":"183","author":"Reizenstein","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"B26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3390\/jcm4020260","article-title":"HPV carcinomas in immunocompromised patients","volume":"4","author":"Reusser","year":"2015","journal-title":"J. Clin. Med."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1546-0096-11-29","article-title":"Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years","volume":"11","author":"Soybilgic","year":"2013","journal-title":"Pediatr. Rheumatol Online J."},{"key":"B28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1071\/SH14015","article-title":"Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives","volume":"11","author":"Toft","year":"2014","journal-title":"Sex Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000357907","article-title":"Human papillomavirus and immunosuppression","volume":"45","author":"Wieland","year":"2014","journal-title":"Curr. Probl Dermatol."},{"key":"B30","volume-title":"1st WHO International Standard for Anti-Human Papillomavirus 18serum","year":"2013"},{"key":"B31","volume-title":"Global strategy to accelerate the elimination of cervical cancer as a public health problem","year":"2020"},{"key":"B32","volume-title":"Human Papillomavirus Laboratory Manual","year":"2009"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1452916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T06:52:16Z","timestamp":1730703136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2024.1452916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":32,"alternative-id":["10.3389\/fcimb.2024.1452916"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2024.1452916","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"article-number":"1452916"}}